VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-21.2%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$77.3M
AUM Growth
+$77.3M
(-25%)
Cap. Flow
+$15.1M
Cap. Flow
% of AUM
19.57%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
3
Closed
–
Top Buys
| 1 |
CTNM
Contineum Therapeutics
CTNM
|
$16.2M |
| 2 |
Skye Bioscience
SKYE
|
$16 |
Top Sells
| 1 |
Passage Bio
PASG
|
$741K |
| 2 |
Aligos Therapeutics
ALGS
|
$302K |
| 3 |
Adverum Biotechnologies
ADVM
|
$7 |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CRISPR Therapeutics
CRSP
$4.71B
| $26.9M | 34.84% | 498,558 | – | – |
|
|
CTNM
2
Contineum Therapeutics
CTNM
$293M
| $16.2M | 20.92% | +918,163 | New | +$16.2M |
|
|
3
Skye Bioscience
SKYE
$108M
| $16.1M | 20.81% | 2,007,704 +2 | +0% | +$16 |
|
4
Repare Therapeutics
RPTX
$71.7M
| $8.73M | 11.3% | 2,646,657 | – | – |
|
|
5
Adverum Biotechnologies
ADVM
$64.6M
| $3.48M | 4.5% | 506,821 -1 | -0% | -$7 |
|
|
6
Passage Bio
PASG
$22.7M
| $3.2M | 4.14% | 4,026,417 -933,352 | -19% | -$741K |
|
|
GRTS
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.2M | 2.85% | 3,561,150 | – | – |
|
|
8
Aligos Therapeutics
ALGS
$73.3M
| $510K | 0.66% | 1,457,937 -862,444 | -37% | -$302K |
|